Glucuronidation in therapeutic drug monitoring

被引:46
|
作者
Shipkova, M
Wieland, E
机构
[1] Klinikum Stuttgart, Zentralinst Klin Chem & Laboratoriumsmed, D-70174 Stuttgart, Germany
[2] Klinikum Stuttgart, Dept Clin Chem & Lab Med, D-70174 Stuttgart, Germany
关键词
glucuronide metabolites; drug monitoring; UGT polymorphisms; drug pharmacokinetic; pharmacologically active metabolites; toxicity;
D O I
10.1016/j.cccn.2005.02.023
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Glucuronidation is a major drug-metabolizing reaction in humans. A pharmacological effect of glucuronide metabolites is frequently neglected and the value of therapeutic drug Monitoring has been questioned, However, this may not always be true. Methods: In this review the impact of glucuronidation on therapeutic drug monitoring, has been evaluated on the basis of a literature search and experience from the own laboratory. Results: The potential role of monitoring glucuronide metabolite concentrations to optimize therapeutic Outcome is addressed on the basis of selected examples of drugs which are metabolized to biologically active reactive glucuronides, Furthermore indirect effects of glucuronide metabolites on parent drug. pharmacokinetics are presented. In addition, factors that may modulate the disposition of these metabolites (e.g. genetic polymorphisms, disease processes, age, and drug drug interactions) are briefly mentioned and their relevance for the clinical Situation is critically discussed. Conclusion: Glucuronide metabolites can have indirect as well as direct pharmacological or toxicological effects. Although convincing evidence to support the introduction Of glucuronide monitoring into clinical practice is currently missing, measurement of glucuronide concentrations may be advantageous in specific situations, If the glucuronide metabolite has an indirect effect on the pharmacokinetics of the parent compound, monitoring of the parent drug may be considered. Furthermore pharmacogenetic approaches considering uridine diphosphate (UDP) glucuronosyltransferases polymorphisms may become useful in the future to optimize therapy with drugs Subject to glucuronidation. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:2 / 23
页数:22
相关论文
共 50 条
  • [21] Challenges in Antifungal Therapy: Therapeutic Drug Monitoring, Drug-Drug Interactions and Approach to Failure After Primary Therapy
    Memisoglu, Funda
    KLIMIK JOURNAL, 2019, 32 : 177 - 186
  • [22] Level of Evidence for Therapeutic Drug Monitoring of Carboplatin
    Hulin, Anne
    Chatelut, Etienne
    Royer, Bernard
    Le Guellec, Chantal
    THERAPIE, 2010, 65 (03): : 157 - 162
  • [23] The use and therapeutic drug monitoring of teicoplanin in the UK
    Darley, ESR
    MacGowan, AP
    CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (01) : 62 - 69
  • [24] Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid
    Ray, J
    Gardiner, I
    Marriott, D
    INTERNAL MEDICINE JOURNAL, 2003, 33 (5-6) : 229 - 234
  • [25] Posaconazole Therapeutic Drug Monitoring in a Regional Hospital Setting
    Lindsay, Patrick J.
    Bond, Stuart E.
    Norris, Ross
    Marriott, Deborah J. E.
    Miyakis, Spiros
    THERAPEUTIC DRUG MONITORING, 2016, 38 (06) : 804 - 807
  • [26] Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic
    Ray, JE
    Marriott, D
    Bloch, MT
    McLachlan, AJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (03) : 291 - 299
  • [27] Current opinions on therapeutic drug monitoring of immunosuppressive drugs
    Shaw, LM
    Holt, DW
    Keown, P
    Venkataramanan, R
    Yatscoff, RW
    CLINICAL THERAPEUTICS, 1999, 21 (10) : 1632 - 1652
  • [28] Clinical benefit of interventions driven by therapeutic drug monitoring
    Rendón, AL
    Núñez, M
    Jiménez-Nácher, I
    de Requena, DG
    González-Lahoz, J
    Soriano, V
    HIV MEDICINE, 2005, 6 (05) : 360 - 365
  • [29] Therapeutic drug monitoring in patients with inflammatory bowel disease
    Andres J Yarur
    Maria T Abreu
    Amar R Deshpande
    David H Kerman
    Daniel A Sussman
    World Journal of Gastroenterology, 2014, (13) : 3475 - 3484
  • [30] THERAPEUTIC DRUG-MONITORING OF ITRACONAZOLE - A REPORT OF EXPERIENCES
    LAMPE, D
    KREUTZBERG, S
    PRUMKE, HJ
    MYCOSES, 1994, 37 : 34 - 39